Ovid Therapeutics Inc.
OVIDNasdaqCIK 1636651HealthcareFiscal year ends Dec 31
Reports and events: 199 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-08-1308:33 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001628280-26-056498 |
| 2026-08-1308:32 ET | 8-K | 9.01 Financial statements and exhibits | 0001628280-26-056497 |
| 2026-07-0807:03 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001628280-26-047584 |
| 2026-06-1109:03 ET | 8-K | 5.07 Shareholder vote results | 0001628280-26-042396 |
| 2026-06-0307:03 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001628280-26-040038 |
| 2026-05-1207:06 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001628280-26-033864 |
| 2026-05-1207:04 ET | 8-K | 9.01 Financial statements and exhibits | 0001628280-26-033859 |
| 2026-04-2717:11 ET | DEF 14A | Proxy statementPeriod 2025-12-31 | 0001628280-26-027621 |
| 2026-04-2008:16 ET | 8-K | 8.01 Other events | 0001628280-26-025926 |
| 2026-03-1816:25 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001628280-26-019438 |
| 2026-03-1807:38 ET | 8-K | 1.01 Entry into a material agreement; 2.02 Results of operations; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001628280-26-019045 |
| 2025-12-1808:39 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-323798 |
| 2025-12-1113:58 ET | 8-K | 5.07 Shareholder vote results | 0001636651-25-000017 |
| 2025-11-1207:04 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001636651-25-000012 |
| 2025-11-1207:02 ET | 8-K | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001636651-25-000011 |
| 2025-11-0706:06 ET | DEF 14A | Proxy statementPeriod 2025-12-11 | 0001140361-25-040884 |
| 2025-10-0317:09 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-230409 |
| 2025-09-1608:00 ET | 8-K | 8.01 Other events | 0001193125-25-204308 |
| 2025-08-1308:03 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001628280-25-040008 |
| 2025-08-1308:02 ET | 8-K | 9.01 Financial statements and exhibits | 0001628280-25-040007 |
| 2025-07-1016:29 ET | 8-K | 5.07 Shareholder vote results | 0001628280-25-034733 |
| 2025-06-2508:22 ET | 8-K | 8.01 Other events | 0001628280-25-032959 |
| 2025-05-2208:04 ET | DEF 14A | Proxy statementPeriod 2024-12-31 | 0001628280-25-027146 |
| 2025-05-1308:08 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001628280-25-024913 |
| 2025-05-1308:06 ET | 8-K | 2.02 Results of operations | 0001628280-25-024911 |
| 2025-05-0216:14 ET | 8-K | 5.08 Item not in the standard list | 0001193125-25-111633 |
| 2025-04-3016:06 ET | 10-K/A | Annual report, amendedPeriod 2024-12-31 | 0001628280-25-021055 |
| 2025-03-1109:08 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001628280-25-011844 |
| 2025-03-1108:51 ET | 8-K | 2.02 Results of operations | 0001628280-25-011839 |
| 2025-03-0516:08 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-25-047174 |
| 2025-02-1317:15 ET | 8-K | 3.01 Delisting notice | 0001193125-25-026192 |
| 2024-11-1208:07 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001628280-24-046868 |
| 2024-11-1208:03 ET | 8-K | 9.01 Financial statements and exhibits | 0001628280-24-046867 |
| 2024-09-1116:57 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-24-217302 |
| 2024-08-1308:03 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001628280-24-036860 |
| 2024-08-1308:02 ET | 8-K | 9.01 Financial statements and exhibits | 0001628280-24-036859 |
| 2024-08-0217:22 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001628280-24-034481 |
| 2024-07-0108:04 ET | 8-K | 8.01 Other events | 0001628280-24-030546 |
| 2024-06-2816:02 ET | 8-K | 2.05 Exit or disposal costs; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure | 0001193125-24-172225 |
| 2024-06-1707:10 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-073998 |
| 2024-06-0716:22 ET | 8-K | 5.07 Shareholder vote results | 0000950170-24-070673 |
| 2024-05-1408:11 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0001628280-24-023067 |
| 2024-05-1408:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-24-023064 |
| 2024-04-2416:57 ET | DEF 14A | Proxy statementPeriod 2024-04-24 | 0000950170-24-047673 |
| 2024-03-0808:24 ET | 10-K | Annual reportPeriod 2023-12-31 | 0001628280-24-009809 |
| 2024-03-0808:20 ET | 8-K | 2.02 Results of operations | 0001628280-24-009807 |
| 2023-12-0617:08 ET | 8-K | 8.01 Other events | 0000950170-23-068591 |
| 2023-11-0308:13 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0001628280-23-036564 |
| 2023-11-0308:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-23-036563 |
| 2023-10-1808:04 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-23-053875 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:14 ET. Listed shows no prices and gives no investment advice.